Slovenian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Stran 1 iz 30 rezultatov
Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Tolcapone (T) is a novel catechol-O-methyltransferase (COMT) inhibitor recently introduced for the treatment of Parkinson's disease. In clinical efficacy studies, T has been associated with a low incidence of diarrhea. The objectives of the study were to examine whether T and its adjunctive drug
Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Catechol-O-methyltransferase (COMT) inhibitors are a new therapeutic option in the treatment of patients with Parkinson's disease. COMT inhibitors act by extending the duration of action of levodopa, thus improving the amount of time a patient can experience benefit from levodopa. COMT inhibitors
Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor that has shown efficacy in the treatment of Parkinson's disease. The authors undertook the first study on the efficacy of this COMT inhibitor in the treatment of major depressive disorder (MDD). The authors also wanted to assess the
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
BACKGROUND
More than 50% of patients with Parkinson's disease develop motor response fluctuations (the "wearing off" phenomenon) after more than five years of levodopa therapy. Inhibition of catechol-O-methyltransferase by tolcapone has been shown to increase levodopa bioavailability and plasma
Safety Profile of Opicapone in the Management of Parkinson's Disease.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Tolcapone increases plasma catecholamine levels in patients with Parkinson's disease.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Tolcapone is a catechol-ortho-methyl-tranferase (COMT) inhibitor that increases the L-DOPA half-life and the duration of effect in Parkinson's disease. We investigated the effect of tolcapone on the plasma catecholamine levels. We measured plasma catecholamines 2h after the first daily dose of
Entacapone.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
OBJECTIVE
To introduce entacapone, a new catechol-O-methyltransferase inhibitor, and discuss its pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, drug interactions, adverse events, dosage guidelines, and therapeutic and formulary considerations.
METHODS
A MEDLINE database search
Toxicology and safety of COMT inhibitors.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
The development of catechol-O-methyltransferase (COMT) inhibitors for the adjunct treatment to levodopa and aromatic L-amino acid decarboxylase (AADC) inhibitors in Parkinson's disease started in the late 1950s. The first-generation inhibitors were associated with toxic properties: they induced
New pharmacotherapy for Parkinson's disease.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
OBJECTIVE
To summarize the development, pharmacology, pharmacokinetics, efficacy, and safety of five investigational antiparkinsonian drugs that are in or have recently completed Phase III trials: three dopamine agonists, pramipexole, ropinirole, and cabergoline; and two catechol-O-methyltransferase
Genetics and gastrointestinal symptoms.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Gastrointestinal (GI) symptoms including nausea, vomiting, diarrhea, constipation, abdominal discomfort/pain, and heartburn are ubiquitous and as such are often the focus of nursing interventions. The etiologies of these symptoms include GI pathology (e.g., cancer, inflammation), dietary factors
Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Recent prospective, double-blind, placebo-controlled trials have examined the long-term effects of the catechol-O-methyl transferase (COMT) inhibitors entacapone and tolcapone as adjuncts to levodopa in PD patients with wearing-off motor fluctuations. These studies demonstrate that both tolcapone
COMT inhibitors in Parkinson's disease.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
The COMT inhibitors, tolcapone and entacapone, are a new class of Parkinson's medications. By inhibiting the enzyme catechol-o-methyl-transferase (COMT), they prevent peripheral degradation of levodopa, allowing a higher concentration to cross the blood-brain barrier. Pharmacokinetic studies have
Tolcapone: a novel approach to Parkinson's disease.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of tolcapone are reviewed. Tolcapone is the first drug brought to market from the new class of selective and reversible inhibitors of catechol-O-methyltransferase. Tolcapone is indicated for use in
A genetic association study of single nucleotide polymorphisms in GNβ3 and COMT in elderly patients with irritable bowel syndrome.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
BACKGROUND
Several polymorphisms have been reported to be associated with irritable bowel syndrome (IBS), including C825T, the single nucleotide polymorphism (SNP), responsible for a truncated G protein β3 subunit (GNβ3), and the Vall158Met substitution in catechol-O-methyltransferase (COMT). We
Practical issues with COMT inhibitors in Parkinson's disease.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Two inhibitors of catechol-O-methyl transferase (COMT), tolcapone and entacapone, have recently been introduced as adjuncts to levodopa in the treatment of Parkinson's disease patients. Both have been shown to provide PD patients with increased "on" time, decreased "off" time, and improved motor
Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo
- Deluje v 55 jezikih
- Zeliščna zdravila, podprta z znanostjo
- Prepoznavanje zelišč po sliki
- Interaktivni GPS zemljevid - označite zelišča na lokaciji (kmalu)
- Preberite znanstvene publikacije, povezane z vašim iskanjem
- Iščite zdravilna zelišča po njihovih učinkih
- Organizirajte svoje interese in bodite na tekočem z raziskavami novic, kliničnimi preskušanji in patenti
Vnesite simptom ali bolezen in preberite o zeliščih, ki bi lahko pomagala, vnesite zelišče in si oglejte bolezni in simptome, proti katerim se uporablja.
* Vse informacije temeljijo na objavljenih znanstvenih raziskavah
